Guggenheim Maintains Buy on AnaptysBio, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja has maintained a Buy rating on AnaptysBio (NASDAQ:ANAB) and increased the price target from $75 to $90.
October 21, 2024 | 5:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim's analyst Yatin Suneja has reaffirmed a Buy rating for AnaptysBio and increased the price target from $75 to $90, indicating confidence in the company's future performance.
The increase in price target from $75 to $90 by a reputable analyst suggests a positive outlook for AnaptysBio, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100